Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia Alessandria, Italy
  • A.O.U. Ospedali Riuniti - Clinica di Ematologia Ancona, Italy
  • Ospedale C. e G. Mazzoni - U.O.C. di Ematologia Ascoli Piceno, Italy
  • AOU Policlinico Consorziale - U.O. Ematologia con Trapianto Bari, Italy
View all 23 locations
View Trial Details
Active, not recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

NCT05546580

Conditions
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Hematologic Diseases, +6 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • The University of Arizona Cancer Center - North Campus Tucson, Arizona, United States
  • Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Miami Cancer Institute Miami, Florida, United States
View all 13 locations
View Trial Details
Active, not recruiting

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

NCT06970743

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Peking University Peoples Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 56 locations
View Trial Details
Active, not recruiting

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

NCT03410875

Conditions
Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Yale University New Haven, Connecticut, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
View Trial Details

Related conditions